<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the treatment of Cushing syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the treatment of Cushing syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the treatment of Cushing syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynnette K Nieman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">André Lacroix, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The hypercortisolemia in Cushing syndrome is usually due to a corticotropin (ACTH)-producing pituitary tumor (Cushing disease), ectopic ACTH secretion by a nonpituitary tumor, or cortisol secretion by an adrenal adenoma or carcinoma. There are also very rare tumors that secrete corticotropin-releasing hormone (CRH) ectopically, and occasional cases are caused by cortisol secretion by ACTH-independent macronodular or micronodular hyperplasia of the adrenal cortex.</p><p>Treatment should be directed, whenever possible, at the primary cause of the syndrome. This topic provides an overview of the various therapeutic options available in the treatment of Cushing syndrome. A detailed review of therapy for Cushing disease and some of the primary adrenal causes of hypercortisolism is presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/118.html" rel="external">"Primary therapy of Cushing disease: Transsphenoidal surgery and pituitary irradiation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16322.html" rel="external">"Persistent or recurrent Cushing disease: Surgical adrenalectomy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/148.html" rel="external">"Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/152.html" rel="external">"Cushing syndrome due to primary pigmented nodular adrenocortical disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/139.html" rel="external">"Diagnosis and management of Cushing syndrome during pregnancy"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H3693166504"><span class="h2">Goals</span><span class="headingEndMark"> — </span>Ideal therapy of Cushing syndrome would achieve the following goals [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Reverse the clinical manifestations by reducing cortisol secretion to normal</p><p class="bulletIndent1"><span class="glyph">●</span>Eradicate any tumor threatening the health of the patient</p><p class="bulletIndent1"><span class="glyph">●</span>Avoid permanent dependence upon medications</p><p class="bulletIndent1"><span class="glyph">●</span>Avoid permanent hormone deficiency</p><p></p><p>In individual patients, however, one or more of the last three goals may have to be sacrificed to achieve the essential first goal. The therapeutic protocols described below proceed from permanently curing the disorder by resecting or ablating its cause to merely controlling the hypercortisolism in patients in whom a cure cannot be achieved. Each stage in the treatment should provide maximum probability of cure with the least chance of permanent endocrine deficiency or other undesirable side effects.</p><p>Specific treatment may be delayed during diagnostic testing or while drug adjustments are made to achieve eucortisolism. During this time, treatment of comorbidities such as hypertension, osteoporosis, and diabetes should be instituted [<a href="#rid3">3</a>]. The use of medications to prevent thrombosis or bone loss should be considered. Treatment should be continued after remission and discontinued only if these comorbidities reverse. Our approach is largely consistent with the Endocrine Society Clinical Practice Guideline [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Exogenous Cushing syndrome</span><span class="headingEndMark"> — </span>The treatment of Cushing syndrome due to exogenous therapy is to stop the glucocorticoid. Most patients who have taken enough glucocorticoid for a long enough time to cause Cushing syndrome will have a period of hypothalamic-pituitary adrenal insufficiency when therapy is discontinued. Thus, gradual withdrawal is necessary. (See  <a class="medical medical_review" href="/d/html/124.html" rel="external">"Pharmacologic use of glucocorticoids"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">CUSHING DISEASE</span><span class="headingEndMark"> — </span>The approach to the treatment of Cushing disease as outlined here is consistent with a 2015 consensus statement on the treatment of corticotropin (ACTH)-dependent Cushing syndrome [<a href="#rid4">4</a>]. </p><p class="headingAnchor" id="H5"><span class="h2">Transsphenoidal surgery</span><span class="headingEndMark"> — </span>The treatment of choice for Cushing disease (ACTH-producing pituitary tumor) is transsphenoidal microadenomectomy when a clearly circumscribed microadenoma can be identified at surgery  (<a class="graphic graphic_algorithm graphicRef76949" href="/d/graphic/76949.html" rel="external">algorithm 1</a>). In the remaining patients, subtotal (85 to 90 percent) resection of the anterior pituitary may be indicated if future fertility is not desired.</p><p>It is difficult to predict residual pituitary function after partial hypophysectomy; some patients have normal pituitary function even after subtotal hypophysectomy. However, the more extensive the resection, the greater the risk of loss of pituitary function. (See  <a class="medical medical_review" href="/d/html/118.html" rel="external">"Primary therapy of Cushing disease: Transsphenoidal surgery and pituitary irradiation"</a>.)</p><p>A practical approach to the uncertainty of surgical localization is to make a contract among the endocrinologist, the patient, and the neurosurgeon before surgery. Among expert pituitary neurosurgeons, the cure rate approximates 70 to 80 percent, but late recurrences reduce the permanent cure rate to approximately 60 to 70 percent. (See  <a class="medical medical_review" href="/d/html/86683.html" rel="external">"Transsphenoidal surgery for pituitary adenomas and other sellar masses"</a>.)</p><p class="headingAnchor" id="H609003423"><span class="h2">Medical therapy</span><span class="headingEndMark"> — </span>Although the hypercortisolism of Cushing disease is optimally treated surgically, medical therapy is often required when surgery is delayed, contraindicated, or unsuccessful. Adrenal enzyme inhibitors are the most commonly used drugs, but adrenolytic agents, drugs that target the pituitary, and glucocorticoid-receptor antagonists also have been used. Medical therapy targeting the corticotroph tumor such as <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> or <a class="drug drug_general" data-topicid="87457" href="/d/drug information/87457.html" rel="external">pasireotide</a> can result in normalization of 24-hour urinary free cortisol in 20 to 40 percent of them, especially if they have only mild hypercortisolism. The glucocorticoid (as well as progestin) antagonist <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> is approved in the United States for treatment of glucose intolerance in patients with Cushing syndrome who are not surgical candidates [<a href="#rid5">5</a>]. This topic is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)"</a>.)</p><p class="headingAnchor" id="H349412676"><span class="h3">Aggressive corticotroph tumors</span><span class="headingEndMark"> — </span>While up to one-third of pituitary tumors, mostly macroadenomas, are locally invasive, a few are more aggressive and 0.1 to 0.2 percent are carcinomas that metastasize in the central nervous system or systemically. These aggressive tumors are resistant to treatment and result in death, usually within several months, or occasionally after several years [<a href="#rid6">6</a>]. Chemotherapy may offer temporary remission in a minority of patients. In a review of 20 patients with aggressive tumors refractory to conventional treatment, the alkylating agent <a class="drug drug_general" data-topicid="9699" href="/d/drug information/9699.html" rel="external">temozolomide</a> resulted in a partial response in approximately two-thirds of patients [<a href="#rid7">7</a>]. The use of immunohistochemical demonstration of low expression of the DNA-repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) appeared to predict responsiveness to the agent. While preliminary, these reports offer a new approach to patients with aggressive or metastatic tumors.</p><p class="headingAnchor" id="H6"><span class="h2">Pituitary irradiation</span><span class="headingEndMark"> — </span>For patients in whom fertility is an important concern and in whom a tumor is not found or who are not cured by transsphenoidal resection of a tumor, pituitary irradiation is one of the next treatment options; it may also be considered as primary therapy for children under age 18 years. Conventional megavoltage linear accelerator after transsphenoidal surgery will correct the hypercortisolism in up to 85 percent of adults when used after debulking surgery and in 85 percent of children when used as monotherapy [<a href="#rid4">4,8,9</a>].</p><p>Maximum benefit is usually achieved within 6 to 12 months, but may require two to three years, and during this time period hypercortisolism should be controlled with one or several adrenal enzyme inhibitors. Pituitary irradiation may also decrease the occurrence of Nelson syndrome in patients not cured by irradiation for whom adrenalectomy becomes necessary, but this has not been tested in a prospective randomized trial.</p><p>Stereotactic radiosurgery (SRS) is the delivery of a single high dose of radiation therapy using a high-precision localization system to treat a small target. SRS is more convenient (a single treatment) than fractionated radiation therapy (many treatments) and provides less irradiation to neuronal tissues It may also provide more rapid biochemical control of cortisol excess than conventional radiation, but this is not well established. </p><p>However, adenomas that are too close, 3 to 5 mm, to radiation-sensitive tissues, such as the optic chiasm or other parts of the optic pathway, are more safely treated with fractionated radiation therapy since a large, single dose of radiation to these tissues can cause blindness. In addition, large adenomas should be treated with conventional radiotherapy. </p><p>In a retrospective study of 278 patients who underwent SRS for Cushing disease, with a mean follow-up of 5.6 years, cumulative control of hypercortisolism at 10 years was 80 percent (mean time to normalization 14.5 months) [<a href="#rid10">10</a>]. However, 18 percent of patients experienced a recurrence after cortisol normalized. This study suggests that a similar percent of patients undergoing SRS or conventional RT eventually have normal cortisols. However, SRS is more convenient, and time to cure may be faster. </p><p class="headingAnchor" id="H7"><span class="h2">Adrenalectomy</span><span class="headingEndMark"> — </span>Bilateral total adrenalectomy with lifelong daily glucocorticoid and mineralocorticoid replacement therapy is the final definitive cure, and may be preferred by some patients instead of radiation therapy. In one series, laparoscopic adrenalectomy was successful in 42 patients with Cushing disease who had not been cured by previous pituitary surgery, radiotherapy and/or medical therapy [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/16322.html" rel="external">"Persistent or recurrent Cushing disease: Surgical adrenalectomy"</a>.)</p><p class="headingAnchor" id="H46368953"><span class="h1">ECTOPIC ACTH AND CRH SYNDROMES</span></p><p class="headingAnchor" id="H46369363"><span class="h2">Ectopic ACTH</span><span class="headingEndMark"> — </span>The optimal therapy of the ectopic corticotropin (ACTH) syndrome (secretion of ACTH by a nonpituitary tumor) is <strong>surgical excision</strong> of the tumor, thereby removing the source of ACTH and curing the metabolic disorder. In several reports, remission occurred after removal of 28 of 34, 10 of 12, and 10 of 26 pulmonary carcinoid tumors and eight of nine localized neuroendocrine or other carcinoid tumors [<a href="#rid12">12-14</a>]. Metastatic tumors cannot be treated by surgical excision.</p><p>In patients with metastases limited to the liver, after resection of the primary tumor, resection or cryoablation of the metastases or even liver transplantation may result in cure [<a href="#rid15">15</a>]. In a study of 103 patients with neuroendocrine carcinomas metastatic to the liver, 60 percent of patients were alive two years after liver transplantation and 47 percent, half of whom were disease-free, were alive after five years [<a href="#rid16">16</a>]. Patients who were less than 50 years old, had primary lung or bowel tumors, and had pretransplant somatostatin treatment had the best prognosis. Depending on the tumor type, chemotherapy and/or radiotherapy may be helpful. (See  <a class="medical medical_review" href="/d/html/2622.html" rel="external">"Diagnosis of carcinoid syndrome and tumor localization"</a>.)</p><p class="headingAnchor" id="H15089050"><span class="h3">Nonresectable tumors</span><span class="headingEndMark"> — </span>For those patients with nonresectable tumors, the hypercortisolism can be controlled with adrenal enzyme inhibitors, such as <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a>, <a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a>, and <a class="drug drug_general" data-topicid="8428" href="/d/drug information/8428.html" rel="external">etomidate</a>. (See  <a class="medical medical_review" href="/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)", section on 'Initial therapy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Therapy with an adrenal enzyme inhibitor can be continued for a prolonged period in patients in whom a tumor cannot be identified. Such patients should be reexamined periodically with 111-In-pentetreotide, computed tomography (CT), or magnetic resonance imaging (MRI) for several years, if necessary, until the tumor can be located and treated [<a href="#rid13">13,14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients have indolent tumors and a long life expectancy but cannot be cured surgically. These patients can be treated with <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a> to achieve a medical adrenalectomy. (See  <a class="medical medical_review" href="/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)"</a>.)</p><p></p><p>Bilateral surgical adrenalectomy or long-term treatment with steroidogenesis inhibitors may be used as an alternative to <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a>  (<a class="graphic graphic_figure graphicRef68665" href="/d/graphic/68665.html" rel="external">figure 1</a>) [<a href="#rid12">12-14</a>].</p><p>Patients whose hypercortisolism is controlled by any means may occasionally develop rebound thymic hyperplasia. Recognition of this condition is important because it may be confused radiologically with tumor recurrence or metastasis in the anterior mediastinum [<a href="#rid17">17</a>].</p><p>Other potential treatment options that have been tried include <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> and <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>The glucocorticoid (as well as progestin) antagonist <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a> has been used to control hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing syndrome and type 2 diabetes or glucose intolerance who have failed surgery or are not candidates for surgery. (See  <a class="medical medical_review" href="/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)", section on 'Glucocorticoid-receptor antagonists'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">Octreotide</a>, a long-acting analogue of somatostatin, rapidly reduces ectopic ACTH secretion by some nonpituitary tumors, but does not usually reduce tumor size [<a href="#rid18">18,19</a>]. Uptake of 111-In-pentetreotide by the tumor also predicts a positive response to the drug [<a href="#rid20">20</a>]. The agent may be given either as a twice-daily or monthly injection and is expensive [<a href="#rid21">21</a>]. It therefore has limited value in treating patients with the ectopic ACTH syndrome.</p><p></p><p class="headingAnchor" id="H46369020"><span class="h2">Ectopic CRH secretion</span><span class="headingEndMark"> — </span>Ectopic corticotropin-releasing hormone (CRH) secretion is a very rare disorder, having been proved in only a small number of cases, mostly with fairly well-differentiated pulmonary carcinoid tumors [<a href="#rid22">22</a>]. The treatment and prognosis of this condition is the same as for ectopic ACTH secretion. The Cushing syndrome can easily be controlled, but the ultimate prognosis depends upon the malignancy of the tumor and whether it can be completely resected.</p><p class="headingAnchor" id="H508841132"><span class="h1">PRIMARY ADRENAL DISEASES</span><span class="headingEndMark"> — </span>Several different adrenal diseases can cause Cushing syndrome; the approach to such patients is generally directed at removal of the adrenal gland(s). Adrenal tumors should be removed with unilateral adrenalectomy while bilateral adrenalectomy is required for bilateral micronodular and most patients with macronodular adrenal hyperplasia. The management of adrenal carcinoma is reviewed separately. (See  <a class="medical medical_review" href="/d/html/165.html" rel="external">"Treatment of adrenocortical carcinoma"</a>.)</p><p class="headingAnchor" id="H508841138"><span class="h2">Adrenal adenomas</span><span class="headingEndMark"> — </span>Some functional adenomas hypersecrete cortisol and cause Cushing syndrome. Approximately 10 percent of cases of overt Cushing syndrome are due to adrenal adenomas. </p><p class="headingAnchor" id="H46368550"><span class="h3">Unilateral adrenalectomy</span><span class="headingEndMark"> — </span>Adenomas are always cured with unilateral adrenalectomy.</p><p class="bulletIndent1"><span class="glyph">●</span>Because of the reduction in postoperative morbidity, hospital stay, and expense compared with open laparotomy, laparoscopic adrenalectomy by an experienced endocrine surgeon is the preferred approach for adrenal adenomas. The laparoscopic approach, which can be done via either the anterior or posterior approaches, has become standard (at least for patients with adenomas &lt;6 cm in diameter). Hospital stays appear to be shorter with this approach (usually one to five days) and complications fewer, as compared with open surgery. Surgical adrenalectomy and details on the anterior and posterior laparoscopic approach are reviewed separately. (See  <a class="medical medical_review" href="/d/html/15027.html" rel="external">"Adrenalectomy techniques", section on 'Selection of operative approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cushing syndrome creates a hypercoagulable state due to an activated coagulation cascade and impaired fibrinolysis and patients have more than a 10-fold greater risk of developing venous thromboembolic disease, particularly if undergoing surgery [<a href="#rid23">23,24</a>]. (See  <a class="medical medical_review" href="/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome", section on 'Thromboembolic events'</a>.)</p><p></p><p class="bulletIndent1">We therefore suggest thromboprophylaxis be used in patients with Cushing syndrome undergoing surgery [<a href="#rid4">4</a>]. The approach to prevention of venous thromboembolism in the surgical patient is reviewed separately. (See  <a class="medical medical_review" href="/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There may be cardiovascular and metabolic benefits to surgery for patients with subclinical Cushing syndrome, who often present with adrenal incidentalomas [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma", section on 'Subclinical Cushing syndrome'</a>.)</p><p></p><p class="headingAnchor" id="H508841144"><span class="h3">Outcome</span><span class="headingEndMark"> — </span>Virtually all patients with adrenocortical adenomas are cured by surgery [<a href="#rid26">26-28</a>]. Postoperative glucocorticoid therapy is needed because excess cortisol secretion has suppressed corticotropin-releasing hormone (CRH) and corticotropin (ACTH). </p><p>In patients with Cushing syndrome due to adrenal adenomas, the recovery of normal ACTH secretion from pituitary corticotropes after prolonged inhibition may be delayed. There will be secondary atrophy of nontumorous adrenal zona fasciculata and reticularis cells in the contralateral adrenal gland. As a result, the patient often requires glucocorticoid replacement therapy for several months to a year and sometimes even longer after resection of the tumor. The principles of glucocorticoid replacement are similar to those for patients with Cushing disease who are cured by resection of a pituitary adenoma. </p><p>Generally, patients are given higher than normal glucocorticoid replacement intraoperatively and postoperatively to avoid symptoms and signs of acute steroid withdrawal. A dose of 150 to 200 mg of <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> (or <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> equivalent if bilateral adrenalectomy is not done) may be administered by constant infusion or in divided doses intravenously over the first 24 hours after induction of anesthesia. A rapid taper follows over a few days until hydrocortisone can be given by mouth. A taper may be achieved by decreasing each successive daily dose to 50 percent of the previous day's dose. </p><p>The patient with subclinical Cushing syndrome with partial suppression of hypothalamic-pituitary-adrenal axis should also be treated with perioperative glucocorticoid coverage because of the risk of adrenal insufficiency; recovery will usually be faster than for patients with severe Cushing syndrome. (See  <a class="medical medical_review" href="/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma", section on 'Subclinical Cushing syndrome'</a>.)</p><p class="headingAnchor" id="H508841150"><span class="h2">ACTH-independent bilateral adrenal hyperplasia</span><span class="headingEndMark"> — </span>There are two forms of ACTH-independent bilateral adrenal hyperplasia: primary pigmented nodular adrenocortical disease (PPNAD, also called micronodular adrenal hyperplasia); and bilateral macronodular adrenal hyperplasia (BMAH). (See  <a class="medical medical_review" href="/d/html/152.html" rel="external">"Cushing syndrome due to primary pigmented nodular adrenocortical disease"</a> and  <a class="medical medical_review" href="/d/html/148.html" rel="external">"Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Surgical bilateral adrenalectomy is uniformly effective in PPNAD; subtotal or unilateral adrenalectomy should not be performed since recurrence can occur. Bilateral adrenalectomy is also indicated in most patients with macronodular adrenal hyperplasia. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bilateral adrenalectomy is now usually performed by laparoscopy and causes permanent adrenal insufficiency, but not Nelson syndrome. In selected cases with macronodular adrenal hyperplasia and aberrant hormone receptors, pharmacologic blockade on the aberrant receptor can result in long-term normalization of cortisol secretion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical management of patients after bilateral adrenalectomy is reviewed separately. (See  <a class="medical medical_review" href="/d/html/16322.html" rel="external">"Persistent or recurrent Cushing disease: Surgical adrenalectomy", section on 'Postoperative management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although medical treatment does not cure ACTH-independent micronodular or macronodular adrenal hyperplasia, the adrenal enzyme inhibitors (<a class="drug drug_general" data-topicid="10156" href="/d/drug information/10156.html" rel="external">metyrapone</a> or <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a>) can be given to reduce cortisol secretion in an attempt to improve the patient's physical condition before surgery. As with adrenocortical tumors, ACTH secretion will not increase and override the pharmacologic blockade. (See  <a class="medical medical_review" href="/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)"</a>.)</p><p></p><p class="headingAnchor" id="H508841156"><span class="h1">COURSE AFTER EFFECTIVE THERAPY</span></p><p class="headingAnchor" id="H3570974964"><span class="h2">Resolution of symptoms and complications</span><span class="headingEndMark"> — </span>Physical symptoms and signs of Cushing syndrome disappear gradually over a period of 2 to 12 months. Overweight, hypertension, and glucose intolerance improve but may not disappear.</p><p>The osteoporosis of Cushing syndrome begins to improve approximately six months after the hypercortisolemia is cured, improves rapidly during the ensuing two years, and more gradually thereafter, but may not normalize [<a href="#rid29">29-31</a>]. For patients with marked bone loss, oral bisphosphonate therapy is recommended; calcium supplementation, vitamin D, and gonadal steroid replacement may also be useful [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis"</a>.)</p><p>In adults, psychiatric symptoms improve, but need for psychopathology may persist, and one study found an increase in the frequency of suicidal ideation and panic [<a href="#rid33">33</a>]. Cognitive deficits persist despite improvement, but not normalization, of apparent brain volume [<a href="#rid34">34,35</a>]. One study of 11 children found a decline in intelligence quotient (IQ) and cognitive performance at one year after curative surgery, in the absence of psychopathology, despite reversal of cerebral atrophy [<a href="#rid36">36</a>].</p><p>In children, bone density and growth rate both increase after treatment, although neither returns to normal [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H4221293962"><span class="h2">Quality of life</span><span class="headingEndMark"> — </span>Cushing syndrome also impairs health-related quality of life (HRQL), which partially, but not completely resolves after transsphenoidal surgery. This was illustrated in a study of 23 patients with Cushing disease who completed a SF (short-form) 36 survey (which evaluates HRQL) before and after transsphenoidal surgery, and in a group of 343 Cushing patients who were in remission for up to 25 years after surgery (mostly pituitary, but some had adrenal or ectopic Cushing) [<a href="#rid38">38</a>]. Active Cushing disease was associated with low physical and mental summary scores on the HRQL survey; after transsphenoidal surgery, all HRQL parameters improved, but did not normalize in these patients.</p><p>Similar results were observed in a meta-analysis of 47 studies in 2643 patients treated for Cushing syndrome [<a href="#rid39">39</a>]. The majority of patients had Cushing disease, but patients with ectopic ACTH secretion and adrenal Cushing were also included. When compared with a healthy control population (n = 2335), all quality-of-life domains improved, but did not normalize. One domain of cognitive functioning normalized after treatment (intelligence), while attention and executive functioning did not. Similar results were seen in a subgroup analysis of patients with Cushing disease. Additional strategies are needed to improve outcomes for patients with persistent impairment of quality of life and/or cognitive functioning after treatment.</p><p>Clinicians typically underestimate the time it takes for patients to recover after surgery [<a href="#rid40">40</a>]. In addition, clinicians perceive that work and exercise are the most important coping mechanisms during recovery. In contrast, most patients consider spending time with family and rest to be the most important activities for recovery. </p><p class="headingAnchor" id="H508841179"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Untreated Cushing syndrome is often fatal, with most deaths being due to cardiovascular, thromboembolic, or hypertensive complications or bacterial or fungal infections. Years ago there was a 50 percent mortality five years after the development of symptoms [<a href="#rid41">41</a>], but the prognosis is much better now. No patient with Cushing syndrome of any cause should die from persistent hypercortisolism, since cortisol production can always be controlled by adrenal enzyme inhibitors, <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a>, or adrenalectomy.</p><p>Cushing disease is virtually always curable, although rarely patients may die of perioperative or other complications [<a href="#rid42">42</a>].</p><p>Patients with ectopic corticotropin (ACTH) secretion or adrenocortical carcinoma may have a poor prognosis associated with the underlying tumor. The prognosis is dictated by the nature of the tumor and the severity of the hypercortisolism. Most patients with overt metastases at the time of presentation die of the cancer within one year, although patients with indolent tumors may survive for many years. Patients with small-cell lung cancer, medullary thyroid cancer, and gastrinoma have a particularly poor prognosis [<a href="#rid13">13,14</a>]. Regardless of the prognosis, no patient should suffer from the effects of persistent hypercortisolism, because it can readily be controlled.</p><p>Patients with severe Cushing syndrome may die from opportunistic infections before completion of diagnostic studies [<a href="#rid43">43-45</a>]. Increased coagulability is also associated with deep vein thrombosis, pulmonary edema, and myocardial infarction [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H1158422206"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112709.html" rel="external">"Society guideline links: Diagnosis and treatment of Cushing syndrome"</a>.)</p><p class="headingAnchor" id="H1187406"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15600.html" rel="external">"Patient education: Cushing syndrome (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2173.html" rel="external">"Patient education: Cushing syndrome (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/2177.html" rel="external">"Patient education: Cushing syndrome treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goal of treatment </strong>–<strong> </strong>The goal of treatment of all patients with Cushing syndrome is to achieve normalization of hypothalamic-pituitary-adrenal function and subsequent reversal of Cushingoid signs/symptoms and comorbidities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery </strong>–<strong> </strong>Optimal treatment involves localization and complete surgical removal of a corticotropin (ACTH)-secreting pituitary or ectopic tumor or cortisol-secreting adrenal tumor(s). (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical therapy </strong>–<strong> </strong>In patients with Cushing disease who were not cured by pituitary surgery, medical therapy targeting the corticotroph tumor such as <a class="drug drug_general" data-topicid="8600" href="/d/drug information/8600.html" rel="external">cabergoline</a> or <a class="drug drug_general" data-topicid="87457" href="/d/drug information/87457.html" rel="external">pasireotide</a> can result in normalization of 24-hour urinary free cortisol in 20 to 40 percent of them, especially if they have only mild hypercortisolism. (See <a class="local">'Medical therapy'</a> above.)</p><p></p><p class="bulletIndent1">Metastatic or occult ectopic ACTH-secreting tumors may respond to somatostatin analog treatment, adrenal enzyme inhibitors, or <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a>. (See <a class="local">'Ectopic ACTH and CRH syndromes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pituitary irradiation </strong>–<strong> </strong>Pituitary irradiation is another second-line treatment for persistent or recurrent Cushing disease. Adrenal enzyme inhibitors must be used to control hypercortisolism until RT is effective. Conventional RT will correct the hypercortisolism in up to 85 percent of adults when used after debulking surgery. (See <a class="local">'Pituitary irradiation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bilateral adrenalectomy </strong>–<strong> </strong>Bilateral adrenalectomy is a definitive treatment for ACTH-secreting pituitary or ectopic tumors. (See <a class="local">'Adrenalectomy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resolution of signs and symptoms </strong>–<strong> </strong>The physical symptoms and signs of Cushing syndrome resolve gradually over a period of 2 to 12 months after effective cure of Cushing syndrome. Hypertension, osteoporosis and glucose intolerance improve but may not disappear. (See <a class="local">'Course after effective therapy'</a> above.)</p><p></p><p class="bulletIndent1">Patients may have impaired quality of life for many years despite remission of hypercortisolism. However, the long-term prognosis of cured patients who had benign disease is excellent. The prognosis of patients with malignancy is variable and relates to the ability to control hypercortisolism and treat the cancer. (See <a class="local">'Prognosis'</a> above and <a class="local">'Ectopic ACTH and CRH syndromes'</a> above.)</p><p></p><p class="headingAnchor" id="H1931849305"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Orth DN. Cushing's syndrome. N Engl J Med 1995; 332:791.</a></li><li><a class="nounderline abstract_t">Orth DN, Liddle GW. Results of treatment in 108 patients with Cushing's syndrome. N Engl J Med 1971; 285:243.</a></li><li><a class="nounderline abstract_t">Nieman LK. Hypertension and Cardiovascular Mortality in Patients with Cushing Syndrome. Endocrinol Metab Clin North Am 2019; 48:717.</a></li><li><a class="nounderline abstract_t">Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100:2807.</a></li><li><a class="nounderline abstract_t">Fleseriu M, Biller BM, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab 2012; 97:2039.</a></li><li><a class="nounderline abstract_t">Kaltsas GA, Mukherjee JJ, Plowman PN, et al. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab 1998; 83:4233.</a></li><li><a class="nounderline abstract_t">Annamalai AK, Dean AF, Kandasamy N, et al. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature. Pituitary 2012; 15:276.</a></li><li><a class="nounderline abstract_t">Estrada J, Boronat M, Mielgo M, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med 1997; 336:172.</a></li><li><a class="nounderline abstract_t">Jennings AS, Liddle GW, Orth DN. Results of treating childhood Cushing's disease with pituitary irradiation. N Engl J Med 1977; 297:957.</a></li><li><a class="nounderline abstract_t">Mehta GU, Ding D, Patibandla MR, et al. Stereotactic Radiosurgery for Cushing Disease: Results of an International, Multicenter Study. J Clin Endocrinol Metab 2017; 102:4284.</a></li><li><a class="nounderline abstract_t">Chow JT, Thompson GB, Grant CS, et al. Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing's syndrome: a review of the Mayo Clinic experience. Clin Endocrinol (Oxf) 2008; 68:513.</a></li><li><a class="nounderline abstract_t">Aniszewski JP, Young WF Jr, Thompson GB, et al. Cushing syndrome due to ectopic adrenocorticotropic hormone secretion. World J Surg 2001; 25:934.</a></li><li><a class="nounderline abstract_t">Ilias I, Torpy DJ, Pacak K, et al. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab 2005; 90:4955.</a></li><li><a class="nounderline abstract_t">Isidori AM, Kaltsas GA, Pozza C, et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab 2006; 91:371.</a></li><li><a class="nounderline abstract_t">Miller CA, Ellison EC. Therapeutic alternatives in metastatic neuroendocrine tumors. Surg Oncol Clin N Am 1998; 7:863.</a></li><li><a class="nounderline abstract_t">Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation 1998; 66:1307.</a></li><li><a class="nounderline abstract_t">Tabarin A, Catargi B, Chanson P, et al. Pseudo-tumours of the thymus after correction of hypercortisolism in patients with ectopic ACTH syndrome: a report of five cases. Clin Endocrinol (Oxf) 1995; 42:207.</a></li><li><a class="nounderline abstract_t">von Werder K, Muller OA, Stalla GK. Somatostatin analogs in ectopic corticotropin production. Metabolism 1996; 45:129.</a></li><li><a class="nounderline abstract_t">Bertagna X, Favrod-Coune C, Escourolle H, et al. Suppression of ectopic adrenocorticotropin secretion by the long-acting somatostatin analog octreotide. J Clin Endocrinol Metab 1989; 68:988.</a></li><li><a class="nounderline abstract_t">Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716.</a></li><li><a class="nounderline abstract_t">Oberg K. Established clinical use of octreotide and lanreotide in oncology. Chemotherapy 2001; 47 Suppl 2:40.</a></li><li><a class="nounderline abstract_t">Ur E, Grossman A. Corticotropin-releasing hormone in health and disease: an update. Acta Endocrinol (Copenh) 1992; 127:193.</a></li><li><a class="nounderline abstract_t">Van Zaane B, Nur E, Squizzato A, et al. Hypercoagulable state in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab 2009; 94:2743.</a></li><li><a class="nounderline abstract_t">Trementino L, Arnaldi G, Appolloni G, et al. Coagulopathy in Cushing's syndrome. Neuroendocrinology 2010; 92 Suppl 1:55.</a></li><li><a class="nounderline abstract_t">Iacobone M, Citton M, Viel G, et al. Adrenalectomy may improve cardiovascular and metabolic impairment and ameliorate quality of life in patients with adrenal incidentalomas and subclinical Cushing's syndrome. Surgery 2012; 152:991.</a></li><li><a class="nounderline abstract_t">Duh QY, Siperstein AE, Clark OH, et al. Laparoscopic adrenalectomy. Comparison of the lateral and posterior approaches. Arch Surg 1996; 131:870.</a></li><li><a class="nounderline abstract_t">Bertagna C, Orth DN. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med 1981; 71:855.</a></li><li><a class="nounderline abstract_t">Välimäki M, Pelkonen R, Porkka L, et al. Long-term results of adrenal surgery in patients with Cushing's syndrome due to adrenocortical adenoma. Clin Endocrinol (Oxf) 1984; 20:229.</a></li><li><a class="nounderline abstract_t">Lufkin EG, Wahner HW, Bergstralh EJ. Reversibility of steroid-induced osteoporosis. Am J Med 1988; 85:887.</a></li><li><a class="nounderline abstract_t">Hermus AR, Smals AG, Swinkels LM, et al. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. J Clin Endocrinol Metab 1995; 80:2859.</a></li><li><a class="nounderline abstract_t">Di Somma C, Pivonello R, Loche S, et al. Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. Clin Endocrinol (Oxf) 2003; 58:302.</a></li><li><a class="nounderline abstract_t">Canalis E, Giustina A. Glucocorticoid-induced osteoporosis: summary of a workshop. J Clin Endocrinol Metab 2001; 86:5681.</a></li><li><a class="nounderline abstract_t">Dorn LD, Burgess ES, Friedman TC, et al. The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 1997; 82:912.</a></li><li><a class="nounderline abstract_t">Bourdeau I, Bard C, Noël B, et al. Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism. J Clin Endocrinol Metab 2002; 87:1949.</a></li><li><a class="nounderline abstract_t">Forget H, Lacroix A, Cohen H. Persistent cognitive impairment following surgical treatment of Cushing's syndrome. Psychoneuroendocrinology 2002; 27:367.</a></li><li><a class="nounderline abstract_t">Merke DP, Giedd JN, Keil MF, et al. Children experience cognitive decline despite reversal of brain atrophy one year after resolution of Cushing syndrome. J Clin Endocrinol Metab 2005; 90:2531.</a></li><li><a class="nounderline abstract_t">Devoe DJ, Miller WL, Conte FA, et al. Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 1997; 82:3196.</a></li><li><a class="nounderline abstract_t">Lindsay JR, Nansel T, Baid S, et al. Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab 2006; 91:447.</a></li><li><a class="nounderline abstract_t">Broersen LHA, Andela CD, Dekkers OM, et al. Improvement but No Normalization of Quality of Life and Cognitive Functioning After Treatment of Cushing Syndrome. J Clin Endocrinol Metab 2019; 104:5325.</a></li><li><a class="nounderline abstract_t">Acree R, Miller CM, Abel BS, et al. Patient and Provider Perspectives on Postsurgical Recovery of Cushing Syndrome. J Endocr Soc 2021; 5:bvab109.</a></li><li><a class="nounderline abstract_t">PLOTZ CM, KNOWLTON AI, RAGAN C. The natural history of Cushing's syndrome. Am J Med 1952; 13:597.</a></li><li><a class="nounderline abstract_t">Jäger F, Heintz A, Junginger T. Synchronous bilateral endoscopic adrenalectomy: experiences after 18 operations. Surg Endosc 2004; 18:314.</a></li><li><a class="nounderline abstract_t">Anthony LB, Greco FA. Pneumocystis carinii pneumonia: a complication of Cushing's syndrome. Ann Intern Med 1981; 94:488.</a></li><li><a class="nounderline abstract_t">Graham BS, Tucker WS Jr. Opportunistic infections in endogenous Cushing's syndrome. Ann Intern Med 1984; 101:334.</a></li><li><a class="nounderline abstract_t">Sarlis NJ, Chanock SJ, Nieman LK. Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab 2000; 85:42.</a></li></ol></div><div id="topicVersionRevision">Topic 174 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7862184" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4326256" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Results of treatment in 108 patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31655772" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hypertension and Cardiovascular Mortality in Patients with Cushing Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26222757" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22466348" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9851756" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22076588" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8988897" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/909542" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Results of treating childhood Cushing's disease with pituitary irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28938462" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Stereotactic Radiosurgery for Cushing Disease: Results of an International, Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17970770" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing's syndrome: a review of the Mayo Clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11572035" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cushing syndrome due to ectopic adrenocorticotropic hormone secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15914534" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16303835" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9735138" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Therapeutic alternatives in metastatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9846513" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7704966" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pseudo-tumours of the thymus after correction of hypercortisolism in patients with ectopic ACTH syndrome: a report of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8769407" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Somatostatin analogs in ectopic corticotropin production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2565915" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Suppression of ectopic adrenocorticotropin secretion by the long-acting somatostatin analog octreotide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8404961" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11275701" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Established clinical use of octreotide and lanreotide in oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1414142" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Corticotropin-releasing hormone in health and disease: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19454584" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hypercoagulable state in Cushing's syndrome: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20829619" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Coagulopathy in Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23158173" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Adrenalectomy may improve cardiovascular and metabolic impairment and ameliorate quality of life in patients with adrenal incidentalomas and subclinical Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8712912" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Laparoscopic adrenalectomy. Comparison of the lateral and posterior approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6272575" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6325048" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-term results of adrenal surgery in patients with Cushing's syndrome due to adrenocortical adenoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3195614" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Reversibility of steroid-induced osteoporosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7559865" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12608935" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11739419" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Glucocorticoid-induced osteoporosis: summary of a workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9062506" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11994323" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11818172" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Persistent cognitive impairment following surgical treatment of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741254" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Children experience cognitive decline despite reversal of brain atrophy one year after resolution of Cushing syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9329338" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16278266" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31276166" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Improvement but No Normalization of Quality of Life and Cognitive Functioning After Treatment of Cushing Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34195531" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Patient and Provider Perspectives on Postsurgical Recovery of Cushing Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12996538" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The natural history of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14691713" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Synchronous bilateral endoscopic adrenalectomy: experiences after 18 operations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6971068" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pneumocystis carinii pneumonia: a complication of Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6331781" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Opportunistic infections in endogenous Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10634361" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
